1. Home
  2. SLDP vs CGEM Comparison

SLDP vs CGEM Comparison

Compare SLDP & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$3.11

Market Cap

848.8M

Sector

Energy

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$15.81

Market Cap

780.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
CGEM
Founded
2011
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
848.8M
780.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SLDP
CGEM
Price
$3.11
$15.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$7.00
$29.89
AVG Volume (30 Days)
3.8M
764.5K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.88
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$5.68
52 Week High
$8.86
$16.74

Technical Indicators

Market Signals
Indicator
SLDP
CGEM
Relative Strength Index (RSI) 30.58 66.47
Support Level $2.92 $6.65
Resistance Level $4.70 $16.74
Average True Range (ATR) 0.19 1.07
MACD 0.00 0.16
Stochastic Oscillator 3.29 78.91

Price Performance

Historical Comparison
SLDP
CGEM

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: